Zhongheng Group announced that Laimei Pharmaceutical, a holding subsidiary of the company, plans to sell the land use rights located at No. 8 Yueji Road, Nan'an District, Chongqing, and the housing buildings and structures above ground through public listing. The initial listing price is not lower than the assessed price of 31.232 million yuan, and the final transaction amount is based on the actual transaction price. This transaction does not constitute a major asset restructuring. It has been reviewed by the board of directors, and there is no need to submit it to the shareholders' meeting for review. The underlying assets are currently secured. Lemei Pharmaceuticals plans to complete the pledge procedure before delivery, and the transaction still needs to go through a public listing procedure. The results are uncertain. If the transaction is based on the assessed price, the estimated impact on net profit is approximately RMB 208.422 million.

Zhongheng Group announced that Laimei Pharmaceutical, a holding subsidiary of the company, plans to sell the land use rights located at No. 8 Yueji Road, Nan'an District, Chongqing, and the housing buildings and structures above ground through public listing. The initial listing price is not lower than the assessed price of 31.232 million yuan, and the final transaction amount is based on the actual transaction price. This transaction does not constitute a major asset restructuring. It has been reviewed by the board of directors, and there is no need to submit it to the shareholders' meeting for review. The underlying assets are currently secured. Laimei Pharmaceuticals plans to complete the pledge procedure before delivery, and the transaction still needs to go through a public listing procedure. The results are uncertain. If the transaction is based on the assessed price, the estimated impact on net profit is approximately RMB 208.422 million.